Topics

RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR AND OSILODROSTAT (LCI699)

14:41 EDT 12 Jul 2019 | FinanzNachrichten

RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR AND OSILODROSTAT (LCI699) Milan, 12 July 2019 - Recordati announces the signing of an agreement with Novartis for the acquisition of worldwide righ...

Original Article: RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR AND OSILODROSTAT (LCI699)

NEXT ARTICLE

More From BioPortfolio on "RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR AND OSILODROSTAT (LCI699)"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...